Partner Content Partner Content 6th Annual Single Cell Analysis USA Congress 2 days, 350+ end users, 80+ case studies
News Pfizer's Tukysa greenlit for earlier use in breast cancer Pfizer gets FDA approval for maintenance use of its oral HER2 inhibitor Tukysa in breast cancer, which it hopes will unlock renewed sales growth.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
